Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Helen Of Troy Making Moves Across Brands To ‘Stabilize’ Personal Care

This article was originally published in The Rose Sheet

Executive Summary

Firm launches new SKUs under its Pert Plus, Brut, Sure and Infusium23 brands as it seeks to stabilize its personal-care business, which has experienced declines for three consecutive quarters in fiscal 2015. Longer-term innovations and improvements in the firm’s struggling appliances segment should help return the division to growth, leadership suggests.

You may also be interested in...



In Brief: Helen Of Troy Buys Supplement Firm; L’Oreal Pore Poll; ICMAD Awards

Helen of Troy’s $195 million acquisition of supplement firm Healthy Directions will increase its revenues by 10% annually, the firm says. More news in brief.

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

L’Oreal Joins J&J And Major Retailers Defending Benzene Class Actions In Federal Courts

Benzoyl peroxide-based acne drug products and their alleged proclivity to become contaminated with carcinogenic benzene are at the center of putative class actions filing against L’Oreal in federal courts around the US.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel